Skip to main content
Top
Published in: Malaria Journal 1/2015

Open Access 01-12-2015 | Commentary

Intermittent presumptive treatment in pregnancy with sulfadoxine–pyrimethamine: a counter perspective

Authors: Francois Nosten, Rose McGready

Published in: Malaria Journal | Issue 1/2015

Login to get access

Abstract

Malaria continues to cause devastation during pregnancy. Unfortunately, there is still no clear strategy to effectively protect pregnant women and countless mothers living in malaria endemic countries are dying every year. The effective prevention of malaria during pregnancy will take much more than the so-called “Global Call for Action” for an intervention (IPTp-SP) that cannot succeed. A new and truly “global” strategy is urgently needed.
Literature
1.
go back to reference Cottrell G, Moussiliou A, Luty AJ, Cot M, Fievet N, Massougbodji A et al (2015) Submicroscopic Plasmodium falciparum infections are associated with maternal anemia, premature births, and low birth weight. Clin Infect Dis 60:1481–1488PubMed Cottrell G, Moussiliou A, Luty AJ, Cot M, Fievet N, Massougbodji A et al (2015) Submicroscopic Plasmodium falciparum infections are associated with maternal anemia, premature births, and low birth weight. Clin Infect Dis 60:1481–1488PubMed
2.
go back to reference McGready R, Lee S, Wiladphaingern J, Ashley E, Rijken M, Boel M et al (2012) Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis 12:388–396PubMedCentralPubMedCrossRef McGready R, Lee S, Wiladphaingern J, Ashley E, Rijken M, Boel M et al (2012) Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis 12:388–396PubMedCentralPubMedCrossRef
3.
go back to reference Chico RM, Dellicour S, Roman E, Mangiaterra V, Coleman J, Menendez C et al (2015) Global call to action: maximize the public health impact of intermittent preventive treatment of malaria in pregnancy in sub-Saharan Africa. Malar J 14:207PubMedCentralPubMedCrossRef Chico RM, Dellicour S, Roman E, Mangiaterra V, Coleman J, Menendez C et al (2015) Global call to action: maximize the public health impact of intermittent preventive treatment of malaria in pregnancy in sub-Saharan Africa. Malar J 14:207PubMedCentralPubMedCrossRef
4.
go back to reference Rijken MJ, McGready R, Boel ME, Poespoprodjo R, Singh N, Syafruddin D et al (2012) Malaria in pregnancy in the Asia-Pacific region. Lancet Infect Dis 12:75–88PubMedCrossRef Rijken MJ, McGready R, Boel ME, Poespoprodjo R, Singh N, Syafruddin D et al (2012) Malaria in pregnancy in the Asia-Pacific region. Lancet Infect Dis 12:75–88PubMedCrossRef
6.
go back to reference McGready R, White NJ, Nosten F (2011) Parasitological efficacy of antimalarials in the treatment and prevention of falciparum malaria in pregnancy 1998 to 2009: a systematic review. BJOG 118:123–135PubMedCrossRef McGready R, White NJ, Nosten F (2011) Parasitological efficacy of antimalarials in the treatment and prevention of falciparum malaria in pregnancy 1998 to 2009: a systematic review. BJOG 118:123–135PubMedCrossRef
7.
go back to reference Harrington WE, Mutabingwa TK, Kabyemela E, Fried M, Duffy PE (2011) Intermittent treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance. Clin Infect Dis 53:224–230PubMedCentralPubMedCrossRef Harrington WE, Mutabingwa TK, Kabyemela E, Fried M, Duffy PE (2011) Intermittent treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance. Clin Infect Dis 53:224–230PubMedCentralPubMedCrossRef
8.
go back to reference Harrington W, McGready R, Muehlenbachs A, Fried M, Nosten F, Duffy P (2012) Intermittent preventive treatment in pregnancy with sulfadoxine–pyrimethamine: the times they are a-changin’. Clin Infect Dis 55:1025–1026PubMedCrossRef Harrington W, McGready R, Muehlenbachs A, Fried M, Nosten F, Duffy P (2012) Intermittent preventive treatment in pregnancy with sulfadoxine–pyrimethamine: the times they are a-changin’. Clin Infect Dis 55:1025–1026PubMedCrossRef
10.
go back to reference Lwin KM, Phyo AP, Tarning J, Hanpithakpong W, Ashley EA, Lee SJ et al (2012) A randomised, double-blind, placebo controlled trial of monthly versus second monthly dihydroartemisinin–piperaquine chemoprevention in adults at high risk of malaria. Antimicrob Agents Chemother 56:1571–1577PubMedCentralPubMedCrossRef Lwin KM, Phyo AP, Tarning J, Hanpithakpong W, Ashley EA, Lee SJ et al (2012) A randomised, double-blind, placebo controlled trial of monthly versus second monthly dihydroartemisinin–piperaquine chemoprevention in adults at high risk of malaria. Antimicrob Agents Chemother 56:1571–1577PubMedCentralPubMedCrossRef
Metadata
Title
Intermittent presumptive treatment in pregnancy with sulfadoxine–pyrimethamine: a counter perspective
Authors
Francois Nosten
Rose McGready
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2015
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/s12936-015-0765-5

Other articles of this Issue 1/2015

Malaria Journal 1/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.